The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or...Read more
PRINCETON, N.J. / Feb 13, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet...Read more
TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation...Read more
First Major Technological Breakthrough in Hyaluronic Acid Dermal Fillers in a Decade; U.S. Launch Planned in Q2 2025 Launch Establishes Evolus as a Multi-Product Performance Beauty Company and Expands Addressable Market by 78% NEWPORT BEACH, Calif. / Feb 13, 2025 / Business Wire / Evolus, Inc....Read more
Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 HOUSTON, Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company...Read more
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and safety as the currently available oral solution New tablet formulation may provide greater freedom...Read more
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Ascendis Pharma | 19.93 15.80 | $146.08 |
| Abbott | 16.80 14.61 | $131.79 |
| AbbVie | 14.25 7.95 | $193.45 |
| Finch Therapeutics | 13.58 754.44 | $15.38 |
| GRAIL | 13.32 33.93 | $52.58 |
| Madrigal Pharmaceuticals | 11.68 3.43 | $351.85 |
| Chemed | 11.11 2.02 | $560.61 |
| Vertex Pharmaceuticals | 10.13 2.24 | $463.33 |
| Tempus AI | 9.87 13.36 | $83.75 |
| HCA Healthcare | 9.54 3.05 | $321.92 |
| Bio-Rad Laboratories | 9.31 2.98 | $321.67 |
| Nutex Health | 9.06 15.54 | $67.36 |
| Regeneron Pharmaceuticals | 8.57 1.29 | $672.43 |
| GE HealthCare | 7.58 8.82 | $93.48 |
| McKesson | 7.47 1.26 | $602.47 |
| Tenet Healthcare | 7.38 5.85 | $133.57 |
| Cigna | 7.13 2.44 | $299.82 |
| GeneDx | 7.03 9.91 | $78.00 |
| Company | Volume | Last Trade |
|---|---|---|
| Aditxt | 152,217,682 | $0.07 |
| ProPhase Labs | 146,698,206 | $0.35 |
| Azitra | 124,487,999 | $0.39 |
| Edesa Biotech | 114,574,184 | $3.17 |
| Moleculin Biotech | 96,471,908 | $1.31 |
| Tivic Health Systems | 79,239,070 | $0.74 |
| Electromedical Technologies | 69,274,832 | $0.00 |
| Senseonics | 55,177,525 | $1.29 |
| Ocean Biomedical | 47,135,847 | $0.15 |
| Avinger | 32,908,205 | $0.62 |
| Tempus AI | 28,909,950 | $83.75 |
| Pfizer | 28,792,975 | $25.64 |
| Recursion | 28,221,623 | $8.50 |
| Syra Health | 22,909,075 | $0.44 |
| Hepion Pharmaceuticals | 21,982,293 | $0.21 |
| CVS Health | 20,389,993 | $66.37 |
| PacBio | 20,288,174 | $1.46 |
| Merck | 18,721,750 | $84.45 |
| Genprex | 16,395,732 | $0.48 |
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
